LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Clara Biotech hits $850K in seed funding roundup, preparing to launch first product
An emerging biotech startup in the region is reporting a busy spring with a significant seed round already raised and key steps under way to launch its product: a solution that removes manufacturing roadblocks for breakthrough drugs. “We’re in an exciting and growing space and currently have low regulatory hurdles in the research stage,” said…
KC pitmaster joins celebrity chefs in ‘BBQ Brawl’; how reality TV pulled Burnt Finger’s pork through 2020 smoke
When Megan Day hits the screen Monday on Food Network, the Lee’s Summit pitmaster, entrepreneur and veteran of TV appearances — from BBQ battles to morning talk shows — could face her greatest challenge to date, she said. “This was a completely different style of competition,” Day, co-founder and face of Burnt Finger BBQ, said of…
Thank you, Black America! Juneteenth pop-up rallies power of KC’s Black creatives
A celebration of Black America — and the critical work it’s done to begin breaking systemic cycles nationwide — is expected to launch soon in Kansas City, promising to shine a light on Black-owned businesses and creators, Kearra Johnson said. “As young, Black entrepreneurs in the city, we’ve been looking for ways to get our brands…
Bad Rhino wants to build, not exit (so investors aren’t playing): Why the fast-paced KC studio hopes to rewrite the game
Midwest investors need to familiarize themselves with the potential waiting to play within the video game industry, said Ryan Manning, noting they otherwise risk losing out on major opportunities. “I don’t mind having those conversations and educating the parties involved,” said Manning, the founder of Bad Rhino Studios. “I think the biggest reason things need…